Highlights Arcturus Therapeutics Holdings Inc.

Equities

ARCT

US03969T1097

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
25.57 ^USD	-3.98%		-8.45%	-18.90%

Mar. 27	Arcturus Therapeutics Holdings Insider Sold Shares Worth $610,574, According to a Recent SEC Filing	MT
Mar. 21	Arcturus Therapeutics Holdings Insider Sold Shares Worth $299,839, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Arcturus Therapeutics Swings to Q4 Net Loss, Revenue Drops	Mar. 07	MT
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Reports Q4 Revenue $34M, vs. Street Est of $37.9M	Mar. 07	MT
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 07	CI
Arcturus Gets European Orphan Medicinal Product Label For ARCT-032 to Treat Cystic Fibrosis	Feb. 22	MT
Passport Technologies, Inc. Commences Collaborative Research with Arcturus Therapeutics to Evaluate Transdermal mRNA Delivery Systems	Jan. 05	CI
CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicronba BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster Booster	Dec. 21	CI
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults	Nov. 28	CI
Arcturus Therapeutics Says FDA Grants Orphan Drug Designation for ARCT-032 to Treat Cystic Fibrosis	Nov. 27	MT
Arcturus Therapeutics Q3 Net Loss Narrows as Revenue Surges; Shares Soar Premarket	Nov. 15	MT
Arcturus Therapeutics Q3 Net Loss Narrows as Revenue Surges	Nov. 14	MT
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Posts Q3 Revenue $45.1M, vs. Street Est of $15.9M	Nov. 14	MT
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Wins Additional Financial Grants from Japanese Government	23-10-04	CI
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA Therapeutic to Treat Cystic Fibrosis	23-09-26	CI
Arcturus Therapeutics Holdings Inc. and Csl Seqirus Announce European Medicines Agency Validates Marketing Authorization Application for Arct-154 Vaccine to Prevent Covid-19	23-09-05	CI
Arcturus Therapeutics Says Arcalis Joint Venture Received $115 Million in Grants From Japanese Government	23-08-14	MT
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-07	CI
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Posts Q2 Revenue $10.5M, vs. Street Est of $49.3M	23-08-07	MT
Arcturus Therapeutics Holdings Inc. Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency	23-06-01	CI
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Arcturus Therapeutics Holdings Inc.

Equities

ARCT

US03969T1097

Highlights

Filters